Compass Point downgraded Horizon Technology (HRZN) to Sell from Neutral with a $10 price target after Evelo Biosciences (EVLO) announced its Phase 2 clinical study with EDP2939 in moderate psoriasis did not achieve the study’s primary endpoint.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRZN: